Powered by

US Nephrologists Beginning to Trial AstraZeneca's LOKELMA (zirconium sodium cyclosilicate) but Unclear on Differentiation from Vifor/Relypsa's VELTASSA (patiromer FOS); According to Spherix Global Insights, nephrologists surveyed in August report increase

Sep 17, 2019 - PR Newswire

PR Newswire

 After two Complete Response Letters resulting in lengthy approval delays, AstraZeneca was finally able to introduce Lokelma, its novel treatment for hyperkalemia, to the US market earlier this year.  Lokelma was acquired from ZS Pharma in 2015 for $2.7 billion.

In the latest quarterly wave ofresearch with US nephrologists(n=105), which has been on-going since Q1 2016, participants were surveyed about their use of Lokelma, Veltassa, and other interventions for hy...